Daraxonrasib extends survival in metastatic pancreatic cancer
1. Daraxonrasib is the first-in-class RAS inhibitor approved for metastatic pancreatic adenocarcinoma, addressing a molecular pathway that drives most pancreatic ...
Tag: progression-free survival
Palbociclib as adjunct maintenance therapy prolongs progression-free survival in some types of metastatic breast cancer
1. This randomized controlled trial found that, in patients with hormone-receptor-positive, HER2-positive metastatic breast cancer, the addition of palbociclib to ...
Switching to camizestrant after ESR1 mutation detection prolongs progression free survival in advanced breast cancer
1. In patients with ER-positive, HER2-negative advanced breast cancer who developed an ESR1 mutation during first-line aromatase inhibitor plus CDK4/6 ...
#Visual Abstract: Targeted Agents Combined with CHOP Increased Response Rates for Peripheral T-Cell Lymphoma
Click here to read this study in the NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
#VisualAbstract: Irinotecan and Temozolomide Plus Dasatinib and Rapamycin Improved Progression-Free Survival for Relapsed or Refrcatory Neuroblastoma
Click here to read this study in Lancet Oncology. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Pembrolizumab improves survival outcomes in cervical cancer patients
1. Patients receiving pembrolizumab with or without platinum-based chemotherapy experienced longer progression-free and overall survival than the placebo group. 2. ...
Relatlimab and nivolumab provide greater survival benefit for advanced melanoma
1. In patients with untreated metastatic or unresectable melanoma, the combination of Relatlimab and Nivolumab was associated with greater progression-free ...
